Penfluridol
SIGMA/P3371 - ≥97% (HPLC), powder
Synonym: 1-
CAS Number: 26864-56-2
Empirical Formula (Hill Notation): C28H27ClF5NO
Molecular Weight: 523.97
EC Number: 248-074-5
MDL Number: MFCD00866714
Linear Formula: C28H27ClF5NO
Product Type: Chemical
| assay | ≥97% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C28H27ClF5NO/c29-26-12 |
| InChI key | MDLAAYDRRZXJIF-UHFFFAOYSA |
| originator | Johnson & Johnson |
| Quality Level | 100 ![]() |
| SMILES string | OC1(CCN(CCCC(c2ccc(F)cc2) |
| solubility | DMSO: >20 mg/mL |
| H2O: insoluble | |
| storage temp. | 2-8°C |
| Application: | Penfluridol has been used as an antipsychotic agent: • to study its antimetastatic effect on triple-negative breast cancer cells • to study its effects on the growth of glioblastoma cell lines, • to study its effects on the vascular endothelial growth factor (VEGF)-induced angiogenesis in human umbilical vein endothelial cells (HUVECs) |
| Biochem/physiol Actions: | Penfluridol is studied in the treatment of schizophrenia, Tourette syndrome and acute psychosis. It also exhibits anticancer activity. |
| Biochem/physiol Actions: | T-type Ca2+ channel blocker; antipsychotic |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 50 mg in glass bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P301 + P310 |
| Hazard Codes | T |
| Risk Statements | 25 |
| Safety Statements | 45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥97% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


